INZY vs. TKNO, MBX, ANAB, KMDA, PRTC, CYRX, ATXS, ABVX, ALLO, and AKBA
Should you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include Alpha Teknova (TKNO), MBX Biosciences (MBX), AnaptysBio (ANAB), Kamada (KMDA), PureTech Health (PRTC), Cryoport (CYRX), Astria Therapeutics (ATXS), ABIVAX Société Anonyme (ABVX), Allogene Therapeutics (ALLO), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry.
Inozyme Pharma vs.
Inozyme Pharma (NASDAQ:INZY) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Inozyme Pharma received 47 more outperform votes than Alpha Teknova when rated by MarketBeat users. Likewise, 87.30% of users gave Inozyme Pharma an outperform vote while only 36.36% of users gave Alpha Teknova an outperform vote.
In the previous week, Inozyme Pharma had 3 more articles in the media than Alpha Teknova. MarketBeat recorded 3 mentions for Inozyme Pharma and 0 mentions for Alpha Teknova. Inozyme Pharma's average media sentiment score of 0.27 beat Alpha Teknova's score of 0.00 indicating that Inozyme Pharma is being referred to more favorably in the media.
Inozyme Pharma has a net margin of 0.00% compared to Alpha Teknova's net margin of -87.17%. Alpha Teknova's return on equity of -35.30% beat Inozyme Pharma's return on equity.
Alpha Teknova has higher revenue and earnings than Inozyme Pharma. Alpha Teknova is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.
88.3% of Inozyme Pharma shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 11.2% of Inozyme Pharma shares are held by insiders. Comparatively, 15.2% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Inozyme Pharma presently has a consensus target price of $18.33, suggesting a potential upside of 1,214.22%. Alpha Teknova has a consensus target price of $5.00, suggesting a potential downside of 38.69%. Given Inozyme Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Inozyme Pharma is more favorable than Alpha Teknova.
Inozyme Pharma has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.
Summary
Inozyme Pharma beats Alpha Teknova on 11 of the 17 factors compared between the two stocks.
Get Inozyme Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inozyme Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:INZY) was last updated on 1/21/2025 by MarketBeat.com Staff
